Pfizer/India Patents (USPTO/Dispute)
Mort Zuckerman
Durlan...@yale.edu, Aa...@columbia.edu, gary_w...@nymc.edu,
scientifi...@ostp.gov, pkru...@princeton.edu,
Stanle...@fiu.edu, emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@po.state.ct.us, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, biz...@nytimes.com, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@po.state.ct.us, kur...@washpost.com,
georg...@washpost.com, p...@allegorypress.com,
commissi...@po.state.ct.us, brans...@comcast.net,
vts...@comcast.net, o...@po.state.ct.us, freet...@charter.net,
scott....@po.state.ct.us, govern...@po.state.ct.us,
attorney...@po.state.ct.us, randall...@usdoj.gov,
Robert....@yale.edu, edi...@greenwich-post.com,
harol...@yale.edu, sedm...@nswbc.org, rrmcg...@aol.com,
fr...@nytimes.com, dpr...@stmartin.edu
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, afa...@niaid.nih.gov,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, amcg...@rms-law.com, rjmu...@aol.com,
paulcrai...@yahoo.com, criminal...@usdoj.gov,
karla.d...@usdoj.gov, christophe...@usdoj.gov,
richar...@yale.edu, harol...@yale.edu, james.p...@yale.edu,
inq...@aldf.com, ly...@idsociety.org, meganm...@theatlantic.com
Subject: Pfizer/India Patents (USPTO/Dispute)
Date: Mar 29, 2010 2:17 AM
ARTICLE BELOW
==============================
I worked for that Patent Infringement
Group at Pfizer. One of our jobs was
to ascertain if our drugs were being
counterfited and if our patented processes
were being used by other countries.
India was a hot spot for this behavior.
While no one would begrudge a company's
human capital investment in drug design
(mostly), India was fed up with US
Multinationals pricing their drugs out
of reach of poorer countries. We could
expect that this is, in fact, the
Globalists' policy, since they want most
darkies to be dead.
One way around patent-persecutions of
poor countries would be to study a
drug and come up with an analog that
had similar efficacy.
Think: Most drugs are just that.
Most drugs are either an accident or
a analog of a natural product.
Quite honestly, Pfizer is not THE
WORST pharmaceutical company.
SmithKline is the worst. They make
the most non-drugs and are nailed
even by our crooked US "law enforcement."
SmithKline and Kaiser have worked together
in criminal cahoots on many products.
In my opinion, the worst thing Pfizer
did was neglect our Lyme/fungal lipid
immunosuppression mechanisms. But all
of America was slammed by WHO and the
European Union over their incompetence
or criminal negligence in this area:
Tuberculosis, the failed Tb vaccines
the failed Lyme vaccines and the
Failed HIV vaccine - with LYMErix
stuck on it, duh.
It woulda been simple. They could have
considered that we Lyme victims were
telling the truth. It coulda been
true that we had the PROOF that we
were telling the truth that we had
a chronic flu-like illness...
This issue is chump-change. *Many* nations
have said they're blowing off claimed
US companies' intellectual property rights.
SOME PEOPLES actually *care* about their
own peoples. Can't be said for the USA.
KMDickson
http://www.actionlyme.org
http://www.relapsingfever.org
================
US Gov Joins Hands With World Pharma Criminal Pfizer To Fight Public
Health Safeguards In Indian Patent Laws
http://timesofindia.indiatimes.com/india/US-patent-office-admits-to-error-in-judgment/articleshow/5736933.cms
US patent office admits to error in judgment
Rema Nagarajan, TNN, Mar 29, 2010, 03.19am IST
*
* Article
*
* Comments
Tags:Pfizer|US Patent and Trademark Office
After joining hands with pharma giant Pfizer to campaign against
public health safeguard clauses in the Indian patents law, the US
Patent and Trademark Office (USPTO) has admitted that they had made a
mistake in co-sponsoring a programme on patent law in India along with
the pharmaceutical giant. USPTO has admitted to glaring conflict of
interest in tying up with a company it was supposed to be regulating.
The USPTO-Pfizer joint programmes in September and October 2009 were
held in Mumbai and Delhi. Under discussion were aspects of the Indian
patents law, such as data exclusivity and specific clauses in the
(Indian) Patents Act, which limit grant of a patent to new medicines
only and not to incremental improvements over known medicines, a
process called evergreening.
In response to protests in blogosphere on this tie-up, Peter Pappas,
chief communications officer of USPTO stated: "It is not the USPTO's
policy or practice to involve private sector rights holders as co-
sponsors of our events. We regret that this occurred with respect to
the Indian forum, but that was the exception and not the rule."
Pappas told TOI, "We have since taken additional steps to ensure that
there are no aberrations from this policy in the future." He refused
to comment on why Dominic Keating, first secretary for intellectual
property at US embassy in Delhi had chosen to hold a public discussion
in co-sponsorship with Pfizer despite such conflict of interest
policies being in place. Pappas also did not answer whether any
clearance had been sought by Keating or given from USPTO office for
holding such a programme.
"[Real] scientists are *fiercely* independent. That's the good
news."-- NIH's Top Fool, Anthony Fauci